231 related articles for article (PubMed ID: 14647248)
1. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
[TBL] [Abstract][Full Text] [Related]
2. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
3. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
4. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL).
Gertz MA; Lacy MQ; Gastineau DA; Inwards DJ; Chen MG; Tefferi A; Kyle RA; Litzow MR
Bone Marrow Transplant; 2000 Nov; 26(9):963-9. PubMed ID: 11100275
[TBL] [Abstract][Full Text] [Related]
5. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
6. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
[TBL] [Abstract][Full Text] [Related]
7. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
8. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.
Maurer MS; Raina A; Hesdorffer C; Bijou R; Colombo P; Deng M; Drusin R; Haythe J; Horn E; Lee SH; Marboe C; Naka Y; Schulman L; Scully B; Shapiro P; Prager K; Radhakrishnan J; Restaino S; Mancini D
Transplantation; 2007 Mar; 83(5):539-45. PubMed ID: 17353770
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
[TBL] [Abstract][Full Text] [Related]
13. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant.
Saba N; Sutton D; Ross H; Siu S; Crump R; Keating A; Stewart A
Bone Marrow Transplant; 1999 Oct; 24(8):853-5. PubMed ID: 10516696
[TBL] [Abstract][Full Text] [Related]
14. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
Gertz MA; Lacy MQ; Dispenzieri A; Ansell SM; Elliott MA; Gastineau DA; Inwards DJ; Micallef IN; Porrata LF; Tefferi A; Litzow MR
Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
[TBL] [Abstract][Full Text] [Related]
15. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
17. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
Porrata LF; Gertz MA; Litzow MR; Lacy MQ; Dispenzieri A; Inwards DJ; Ansell SM; Micallef IN; Gastineau DA; Elliott M; Hogan WJ; Hayman SR; Tefferi A; Markovic SN
Clin Cancer Res; 2005 Feb; 11(3):1210-8. PubMed ID: 15709191
[TBL] [Abstract][Full Text] [Related]
18. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis.
Dingli D; Tan TS; Kumar SK; Buadi FK; Dispenzieri A; Hayman SR; Lacy MQ; Gastineau DA; Hogan WJ; Gertz MA
Neurology; 2010 Mar; 74(11):913-8. PubMed ID: 20231668
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
20. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
